Vident Core U.S. Equity Fund (NYSEARCA:VUSE – Get Free Report) traded down 0.2% during trading on Monday . The company traded as low as $57.60 and last traded at $57.64. 12,271 shares changed hands during trading, a decline of 29% from the average session volume of 17,298 shares. The stock had previously closed at $57.77.
Vident Core U.S. Equity Fund Stock Down 0.2 %
The business’s fifty day moving average price is $56.82 and its 200 day moving average price is $54.84. The firm has a market capitalization of $610.98 million, a PE ratio of 17.39 and a beta of 0.94.
Institutional Investors Weigh In On Vident Core U.S. Equity Fund
Institutional investors have recently bought and sold shares of the stock. Kings Path Partners LLC purchased a new stake in Vident Core U.S. Equity Fund in the third quarter valued at approximately $153,000. Mather Group LLC. purchased a new stake in Vident Core U.S. Equity Fund in the second quarter valued at approximately $179,000. Oak Harvest Investment Services purchased a new stake in Vident Core U.S. Equity Fund in the second quarter valued at approximately $201,000. Willner & Heller LLC purchased a new stake in Vident Core U.S. Equity Fund in the second quarter valued at approximately $215,000. Finally, Foundations Investment Advisors LLC purchased a new stake in Vident Core U.S. Equity Fund in the third quarter valued at approximately $320,000.
About Vident Core U.S. Equity Fund
The Vident Core U.S. Equity Fund (VUSE) is an exchange-traded fund that is based on the Vident Core U.S. Stock index. The fund tracks an index of US companies selected and weighted based on a multi-factor model that considers corporate governance, quality, and momentum. VUSE was launched on Jan 22, 2014 and is managed by Vident.
Further Reading
- Five stocks we like better than Vident Core U.S. Equity Fund
- What Are Dividends? Buy the Best Dividend Stocks
- Intel: Is Now the Time to Be Brave?
- Why Invest in 5G? How to Invest in 5G Stocks
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What Do S&P 500 Stocks Tell Investors About the Market?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Vident Core U.S. Equity Fund Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vident Core U.S. Equity Fund and related companies with MarketBeat.com's FREE daily email newsletter.